ALK and non-small cell lung carcinoma: The clinical outcome for ALK-rearranged NSCLC patients has dramatically changed in recent years thanks to the introduction in clinical practice of efficient ALK-i, which is able to significantly stop tumor growth and to guarantee patients long survival with high quality of life.